HI SCR227

Requests the Department of Health to convene a Medicinal Psilocybin and Psilocin Working Group to examine the medicinal and therapeutic effects of psilocybin and psilocin for treating mental health conditions.

Working group to examine federal, state, and local laws regarding medicinal use of psilocybin and psilocin; medical and scientific research on safety and efficacy; and requirements for medical professionals to prescribe these substances.

Working group to develop a long-term strategic plan to ensure availability of medicinal psilocybin and psilocin products that are safe, accessible, and affordable for adults 21 years of age or older.

Working group composition includes Director of Health (chair), Attorney General, University of Hawaii faculty, legislative committee chairs, clinical practitioners, and representatives from the Drug Policy Forum of Hawaii, Clarity Project, Hawaii Psychiatric Medical Association, and the public, with maximum 15 members.

Working group must submit preliminary report to Legislature by 20 days before 2023 Regular Session and final report with proposed legislation by 20 days before 2024 Regular Session; working group dissolves July 1, 2024.